Abstracts tagged "Outcome measures"

Abstract Number: 2018 • ACR Convergence 2022
Five Year Follow-up of Systemic Disease Activity Measured with the ESSDAI in a Standard of Care Cohort of Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Alja Stel³, Greetje van Zuiden³, Jolien van Nimwegen², Arjan Vissink⁴, Frans Kroese², Gwenny Verstappen² and Hendrika Bootsma², ¹UMCG, Zwolle, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is often used as primary endpoint in randomised clinical trials (RCTs) in patients with primary Sjögren's…
Abstract Number: 2238 • ACR Convergence 2022
Performance of the 2016 ACR/EULAR Myositis Response Criteria in Adult Dermatomyositis and Polymyositis Therapeutic Trials and Consensus Profiles
Didem Saygin¹, Hanna Kim², Christian Douglas³, Brian Erman³, Jesse Wilkerson³, john mcgrath³, Chester Oddis⁴, Ingrid Lundberg⁵, Anthony Amato⁶, Ignacio Garcia-De La Torre⁷, Hector Chinoy⁸, David Fiorentino⁹, Lorinda Chung⁹, Yeong-Wook Song¹⁰, Katalin Danko¹¹, Frederick Miller¹², Nicola Ruperto¹³, Jiří Vencovský¹⁴, Rohit Aggarwal¹⁵ and Lisa G Rider¹², ¹University of Chicago, Chicago, IL, ²Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ³Social and Scientific Systems, Inc., Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁶Harvard University, Boston, MA, ⁷Centro de Est. de Inv. Bas. y Clinica, S.C., Guadalajara, Mexico, ⁸The University of Manchester, Sale, United Kingdom, ⁹Stanford University, Stanford, CA, ¹⁰Seoul National University, Seoul, Republic of Korea, ¹¹*Deceased, Debrecen, Hungary, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ACR/EULAR myositis response criteria (MRC) were developed as a composite continuous measure (Total Improvement Score (TIS)) using absolute percent changes (abs%) in 6…
Abstract Number: 0231 • ACR Convergence 2022
Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
Camille Bourgeois¹, Jorge Olmedo Galindo², Juan Molina¹, Gema Fernandez-Plana², Julia Martinez-Barrio¹, Javier Rivera³ and Isabel Castrejon⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Gerencia Asistencial Atención Primaria, Comunidad de Madrid, Madrid, Spain, ³Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Primary care physicians (PCPs) play a crucial role in early recognition and rapid referral of patients with inflammatory arthritis to improve early management and…
Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
Abstract Number: 1028 • ACR Convergence 2022
How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA?
Conor Coyle¹, Caroline Whately-Smith², Melanie Brooke³, Uta Kiltz⁴, Ennio Lubrano⁵, Ruben Queiro⁶, David Trigos⁷, Jan Brandt-Juergens⁸, Salvatore D'Angelo⁹, Andrea Delle Sedie¹⁰, Emmanuelle Dernis¹¹, Philip Helliwell¹², Pauline Ho¹³, Axel Hueber¹⁴, BEATRIZ E. JOVEN¹⁵, Michaela Koehm¹⁶, Carlos Montilla¹⁷, Jon Packham¹⁸, JOSE PINTO TASENDE¹⁹, Felipe Julio Ramirez Garcia²⁰, Adeline Ruyssen-Witrand²¹, Rossana Scrivo²², sarah twigg²³, Martin Welcker²⁴, Theo Wirth²⁵, Laure Gossec²⁶ and Laura Coates²⁷, ¹Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ²Whately-Smith Ltd, Kings Langley, United Kingdom, ³Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶Faculty of Medicine, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Universidad de Oviedo, Oveido, Spain, ⁷Patient partner, Oveido, Spain, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ¹⁰University of Pisa, Pisa, Pisa, Italy, ¹¹LE MANS general hospital, LE MANS, France, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹³The Kellgren Centre for Rheumatology, Manchester, United Kingdom, ¹⁴Paracelsus University Nürnberg, Erlangen, Germany, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ¹⁷Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁸University of Nottingham, Stafford, United Kingdom, ¹⁹SERGAS, A Coruña, Spain, ²⁰Hospital Clínic, Barcelona, Spain, ²¹CHU de Toulouse, Toulouse, France, ²²Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ²³Bradford Teaching hospitals NHS foundation trust, Bradford, United Kingdom, ²⁴GBR, Planegg, Germany, ²⁵Aix Marseille University, Marseille, France, ²⁶Sorbonne Université, Paris, France, ²⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous, multi-dimensional disease. Little is known about factors underpinning treatment intensification in routine practice. Treatment pathways are not well…
Abstract Number: 1362 • ACR Convergence 2022
Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles
Hanna Kim¹, Didem Saygin², Christian Douglas³, john mcgrath³, Jesse Wilkerson³, angela Pistorio⁴, Ann Reed⁵, Chester Oddis⁶, Frederick Miller⁷, Jiří Vencovský⁸, Nicola Ruperto⁹, Rohit Aggarwal¹⁰ and Lisa G Rider⁷, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ²University of Chicago, Chicago, IL, ³Social and Scientific Systems, Inc., Durham, NC, ⁴IRCCS Istituto Giannina Gaslini, Genoa, Italy, ⁵Duke University School of Medicine, Durham, NC, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Juvenile dermatomyositis (JDM) ACR-EULAR myositis response criteria (MRC) were developed based on absolute % changes in 6 core set measures (CSM) differentially weighted to…
Abstract Number: 1642 • ACR Convergence 2022
Mast Cells May Explain Sex Differences in Osteoarthritis Pain
Bella Mehta¹, Edward DiCarlo², Fei Wang³, Miguel Otero⁴, Eun Kyung Song⁵, Peter Sculco², Mark Figgie², Susan Goodman², William Robinson⁵ and Dana Orange⁶, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Weil Cornell Medical College, New York, NY, ⁴Hospital for Special Surgery Research Institute, New York, NY, ⁵Stanford University School of Medicine, Palo Alto, CA, ⁶The Rockefeller University, New York, NY
Background/Purpose: Women are at increased risk for knee osteoarthritis(OA) and report more severe pain than men at the time of total knee arthroplasty. It has…
Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Astrid Rasmussen¹, R. Hal Scofield², Kiely Grundahl¹, Lida Radfar², Christopher Lessard¹ and A. Darise Farris¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: 0260 • ACR Convergence 2022
Impacts of Poor Prognostic Factors in Rheumatoid Arthritis on Clinical Outcomes and Treatment Choices from an Observational Cohort of Korean Patients with Rheumatoid Arthritis
You-Jung Ha¹, Seunghwan Shin², SE RIM CHOI³, Eun Ha Kang¹ and Yun Jong Lee¹, ¹Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ²Lunit Inc, Seoul, Republic of Korea, ³Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: The primary target for the treatment of rheumatoid arthritis (RA) is achieving remission or low disease activity with proper use of DMARD. Besides controlling…
Abstract Number: 0634 • ACR Convergence 2022
Total Interstitial Inflammation Predicts Chronic Kidney Disease Progression in Patients with Lupus Nephritis
Minh Dien Duong¹, Shudan Wang², Daniel Schwartz³, Wenzhu B. Mowrey⁴, Anna Broder⁵ and Beatrice Goilav⁶, ¹The Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Children's Hospital of Montefiore / Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Kidney biopsy is a gold standard for diagnosis and prognostication of lupus nephritis (LN). While interstitial fibrosis and tubular atrophy (IFTA) predict progression to…
Abstract Number: 1055 • ACR Convergence 2022
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
Alex Luta¹, Saloni Godbole¹ and Virginia Steen², ¹Medstar Georgetown University Hospital, Washington, DC, ²Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
Abstract Number: 1364 • ACR Convergence 2022
Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the the Juvenile Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Ana Paula Sakamoto⁷, Brian Feldman⁸, FLAVIO SZTAJNBOK⁹, Valda Stanevica¹⁰, Jordi Anton¹¹, Sindu Johnson¹², Raju Khubchandani¹³, Ekaterina Alexeeva¹⁴, Maria Katsicas¹⁵, Sujata Sawhney¹⁶, Vanessa Smith¹⁷, Simone Appenzeller¹⁸, Tadey Avcin¹⁹, Mikhail Kostik²⁰, Thomas Lehman²¹, Hana Malcova²², Edoardo Marrani²³, Clare Pain²⁴, Dieneke Schonenberg-Meinema²⁵, Walter Alberto Sifuentes-Giraldo²⁶, Natalia Vasquez-Canizares²⁷, Patricia Costa Reis²⁸, Mahesh Janarthanan²⁹, Dana Nemcova³⁰, Anjali Patwardhan³¹, Maria José Santos³², Sima Abu Alsaoud³³, Cristina Battagliotti³⁴, Lillemor Berntson³⁵, Blanca Bica³⁶, Jürgen Brunner³⁶, Rolando Cimaz³⁷, Despina Eleftheriou³⁸, Liora Harel³⁹, Gerd Horneff⁴⁰, Daniela Kaiser⁴¹, Tilmann Kallinich⁴², Dragana Lazarevic⁴³, Farzana Nuruzzaman⁴⁴ and Nicola Helmus⁴⁵, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ⁴Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey, ⁵Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ⁶Universidad Federal São Paulo, São Paulo, Brazil, ⁷Federal University of Sao Paulo (UNIFESP), São Paulo, Brazil, ⁸Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁹UFRJ/UERJ, São Paulo, Brazil, ¹⁰Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹¹Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹²University of Toronto, Toronto, ON, Canada, ¹³SRCC Children's Hospital, Mumbai, India, ¹⁴National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation,, Moscow, Russia, ¹⁵Hospital Garrahan, Buenos Aires, Argentina, ¹⁶Sir Ganga Ram Hospital, Sector 37 noida, Uttar Pradesh, India, ¹⁷Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ¹⁸Unicamp, Campinas, São Paulo, Brazil, ¹⁹University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ²⁰Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ²¹Hospital for Special Surgery, New York, NY, ²²Motol University Hospital, Prague, Czech Republic, ²³University of Florence, Firenze, Italy, ²⁴Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom, ²⁵Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²⁶Hospital Universitario Ramon y Cajal, Madrid, Spain, ²⁷Children’s Hospital at Montefiore, Bronx, NY, ²⁸Hospital de Santa Maria, Lisbon, Portugal, ²⁹SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ³⁰Charles University, Prague, Czech Republic, ³¹University of Missouri, Columbia, MO, ³²Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ³³Makassed, Jerusalem, Israel, ³⁴Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ³⁵Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ³⁶UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ³⁷University of Milano, Milano, Italy, ³⁸Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ³⁹Schneider Children's Medical center, Tel Aviv University, Nettnja, Israel, ⁴⁰Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴¹Children's Hospital Lucerne, Lucerne, Switzerland, ⁴²Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁴³Faculty of Medicine, University of Niš, Nis, Serbia, ⁴⁴Stony Brook Children's Hospital, East Setauket, NY, ⁴⁵Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. In adult patients there are significant…
Abstract Number: 1706 • ACR Convergence 2022
Clinical and Immunological Factors Associated with Chronic Post-COVID19 Syndrome 12 Months After Acute Infection
Emmanuel Abimelec Camacho-Morán¹, jiram torres-Ruiz¹, Jaquelin Lira-Luna¹, Ana Sofía Vargas-Castro², Alfredo Pérez-Fragoso¹, Miroslava Nuñez-Aguirre², Beatriz Alcalá-Carmona³, Abdiel Absalón-Aguilar³ and Diana Gómez-Martín¹, ¹INCMNSZ, Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Background/Purpose: Post-COVID19 syndrome has been defined as the persistence of symptoms and/or organic damage for more than three weeks after the presence of clinical infection…
Abstract Number: 2054 • ACR Convergence 2022
Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process
Kathryn Connelly¹, Laura Eades², Rachel Koelmeyer³, Darshini Ayton³, Vera Golder², Rangi Kandane-Rathnayake², Kate Gregory-Wong³, Hussein Al-Mossawi⁴, Jeanette Andersen⁵, Cynthia Aranow⁶, Laurent Arnaud⁷, Anca Askanase⁸, Subhashis Banerjee⁹, Catherine Barbey¹⁰, Hermine Brunner¹¹, Joy Buie¹², Laurie Burke¹³, Alain Cornet¹⁴, Karen Costenbader¹⁵, Maria Dall'Era¹⁶, Khadija Dantata¹⁷, Nikolay Delev⁹, Ann Eldred¹⁸, Alan Friedman¹⁹, Richard Furie²⁰, Sandra Garces²¹, Dennis Grasela²², Heath Guay²³, Oliver Guenther²⁴, Maria Juarez²⁵, Shelly Kafka²⁶, Kenneth Kalunian²⁷, Elaine Karis²⁸, Youmna Lahoud²⁹, Catharina Lindholm³⁰, Jeffrey Lockman³¹, Charlotte Lupton³², Justine Maller³³, Ashley Marion³⁴, Patrick Marquis³⁵, Joan Merrill³⁶, Thomas Morel³⁷, Marta Mosca³⁸, Yulia Pincus³⁹, Samantha Pomponi⁴⁰, Guillermo Pons-Estel⁴¹, Jorge Ross Terres³³, Cailin Sibley⁴², Maria Silk⁴³, Sanjeev Roy⁴⁴, Lee S Simon⁴⁵, Alessandro Sorrentino⁴⁶, Christian Stach⁴⁷, George Stojan⁴⁸, Ying Sun²⁴, Yoshiya Tanaka⁴⁹, Erik Thomas⁵⁰, Ronald van Vollenhoven⁵¹, Cristina Vazquez Mateo⁵⁰, Edward M Vital⁵², Victoria Werth⁵³, Eric Zollars²⁸, Qing Zuraw⁵⁴ and Eric Morand⁵⁵, ¹Monash Health, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴AstraZeneca, Bucks, United Kingdom, ⁵Lupus Europe, Lupus DK, EULAR PARE, ERN ReCONNECT, Brussels, Belgium, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France, ⁸Columbia University Medical Center, New York, NY, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Biogen, Baar, Switzerland, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ¹²Lupus Foundation of America, Charleston, SC, ¹³LORA Group, Royal Oak, MD, ¹⁴Lupus Europe, Brussels, Belgium, ¹⁵Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, Division of Rheumatology, San Francisco, CA, ¹⁷Lupus Foundation of America, Richmond Hill, GA, ¹⁸AbbVie, Inc., Lake Bluff, IL, ¹⁹AbbVie, Inc., Libertyville, IL, ²⁰Northwell Health, Great Neck, NY, ²¹Amgen, Inc., Almada, Portugal, ²²Bristol Myers Squibb, Lawrencevile, NJ, ²³AbbVie, Inc., Worcester, MA, ²⁴Merck KGaA, Darmstadt, Germany, ²⁵UCB Pharma, Slough, United Kingdom, ²⁶AbbVie, Inc., Norristown, PA, ²⁷University of California San Diego, La Jolla, CA, ²⁸Amgen, Inc., Thousand Oaks, CA, ²⁹Biogen International GmbH, Milton, MA, ³⁰AstraZeneca, Gothenburg, Sweden, ³¹Bristol-Myers Squibb, New York, NY, ³²AstraZeneca, Cambridge, United Kingdom, ³³Genentech, San Francisco, CA, ³⁴Lupus Foundation of America, Washington, DC, ³⁵Modus Outcomes, Cambridge, MA, ³⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁷UCB Pharma, Brussels, Belgium, ³⁸University of Pisa, Pisa, Italy, ³⁹Janssen, Flemington, NJ, ⁴⁰Bristol Myers Squibb, Lawrence Township, NJ, ⁴¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, Rosario, Argentina, ⁴²Janssen Research & Development, San Diego, CA, ⁴³Eli Lilly, Carmel, IN, ⁴⁴Global Clinical Development, Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany,⁴⁵SDG LLC, West Newton, MA,⁴⁶AstraZeneca, Sollentuna, Sweden, ⁴⁷UCB Pharma, Monheim, ⁴⁸UCB Pharma, Baltimore, MD, ⁴⁹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁵⁰EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, ⁵¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁵⁴Janssen Research and Development, LLC, Spring House, PA, ⁵⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Most late-phase randomised controlled trials (RCTs) of novel drugs for systemic lupus erythematosus (SLE) have failed to meet their primary endpoint or shown contradictory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.